Colorado BioScience Association appoints new board leadership

Wednesday, May 24, 2017

Terumo BCT General Counsel Scott Larson named chairman of the board  

Nivalis Therapeutics acquired by Seattle-based Alpine Immune Systems

Tuesday, April 18, 2017

A Seattle biotech company is acquiring Boulder’s Nivalis Therapeutics, merging with it to become publicly traded and use Nivalis’ $44 million in cash to fund new immunotherapy cancer and inflammatory disease treatments. 

Taiga Biotechnologies raises $6 million

Thursday, March 30, 2017

The University of Colorado Anschutz Medical Campus startup is well on its way to raising a targeted $14 million. Taiga's previous capital raises included $12 million in 2015. 

CU Boulder Study: Federally-Funded Laboratories and Institutions Have a $2.6 Billion Annual Impact in Colorado

Thursday, March 23, 2017

CU Boulder Study: Federally-Funded Laboratories and Institutions Have a $2.6 Billion Annual Impact in Colorado  

Ag biotech firm Front Range Biosciences raises $1.5M

Thursday, March 16, 2017

Front Range Biosciences Inc., a startup agricultural biotech firm based in Lafayette, has raised $1.5 million in funding from five venture-capital firms. 

E.I. Medical Imaging Partners With Denver Zoo to Welcome Baby Giraffe Dobby

Tuesday, March 14, 2017

Loveland, Colorado, March 14, 2017 ( - With all of the excitement around baby giraffes these days, E.I. Medical Imaging (EIMI) is proud to announce that their EVO® ultrasound system was instrumental in determining the pregnancy of Denver Zoo's Kipele. With a complete team effort and some remote viewing technology, the keepers and veterinary staff from Denver Zoo were able to determine and confirm Kipele's pregnancy and prepare for the subsequent birth of baby Dobby. 

ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial

Monday, March 06, 2017

WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the 175th patient has been randomized into GENETIC-AF, a seamless design Phase 2B/3 clinical trial evaluating Gencaro™ (bucindolol hydrochloride) as a potential treatment for atrial fibrillation (AF). 

Matrix Analytics receives $250,000 investment from Mark Cuban

Friday, March 03, 2017

A Denver company that makes health-care software said "Shark Tank" TV show star and Dallas Mavericks owner Mark Cuban has invested in the company. 

Muse Bio Raises $23 million

Friday, March 03, 2017


MiRagen raises $40.7 million, goes public with Signal Genetics merger

Tuesday, February 14, 2017

BOULDER — Clinical-stage biopharmaceutical company MiRagen Therapeutics Inc. has completed its merger with a publicly traded California company, raising $40.7 million in private equity financing just prior to the deal. MiRagen begins trading Tuesday on the Nasdaq exchange under the ticker symbol “MGEN.”